Replies to post #186963 on Biotech Values

[DewDiligence]

GILD’s average US rebate on HCV sales is expected to be 46% going forward. This is probably why the share price is falling in AH trading.

This 46% figure includes Sovaldi as well as Harvoni; GILD did not break out the expected average rebate for Harvoni, specifically.